On May 26, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstracts demonstrate NeoGenomics’ expanding capabilities across the company’s clinical oncology testing and data solutions, spanning hematologic malignancies, solid-tumor genomic profiling, the real-world impact of insurance coverage gaps on next-generation sequencing (NGS) testing, and the detection of circulating tumor DNA (ctDNA) through molecular residual disease (MRD). These findings include an online presentation on the utilization of RaDaR ST in a colorectal cancer cohort, as reflected in an interim analysis from a collaboration with investigators at MD Anderson Cancer Center.

To support biopharma partners advancing ADCs, BiTES, bispecifics, radioligands, and targeted therapies, NeoGenomics will highlight new biomarkers, including B7-H3, CD137, EZH2, and PRMT5. The company is also developing a low-sample-input acute myeloid leukemia (AML) MRD flow assay designed to deliver higher sensitivity and faster turnaround times compared to currently available assays. This approach may enable more confident relapse risk prediction, therapeutic response assessment, and MRD endpoint tracking in hematologic trials, even when sample availability is limited.

NeoGenomics will also debut its updated mission, partnering with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes, and a new vision of a world where every cancer treatment decision is as personal as the patient. Both will be reflected throughout the booth, alongside the company’s new tagline, ‘Answers are in our DNA.’

"A cancer diagnosis is the beginning of a long road, and NeoGenomics is committed to being there from first diagnosis through recurrence monitoring," said Tony Zook, CEO of NeoGenomics. "The breadth of our ASCO (Free ASCO Whitepaper) research and a sharpened mission reflect our commitment to providing personalized answers for every cancer patient."

Presentations and online abstracts at ASCO (Free ASCO Whitepaper) include:

Poster #177: Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS Testing
Session: Quality Care/Health Services Research
Monday, June 1, 9 AM to 12 PM CDT | Hall A
Poster #337: From Infancy to Young Adulthood: Exploring the divergent genomic mechanisms that drive AML
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Monday, June 1, 9 AM to 12 PM CDT | Hall A
Poster #129a: Interception of Molecular Relapse in Breast Cancer: The SURVIVE HERoes Study (NCT06643585)
Session: Breast Cancer—Local/Regional/Adjuvant
Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
Poster #135a: The SURVIVE Study: Re-evaluating Follow-up in Early Breast Cancer
Session: Breast Cancer—Local/Regional/Adjuvant
Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
Online Abstract: Concordance of liquid biopsy and tissue CGP for identification of guideline-recommended actionable variants
Online Abstract: Real-world evidence for comprehensive genomic profiling in myeloid malignancies: changes in detection and clinical impact
Online Abstract: Exploration of tumor-informed ctDNA detection and dynamics in a real-world cohort of colorectal cancer patients from the MD Anderson Cancer Center
Online Abstract: Clinical actionability and molecular landscapes of fusion-driven sarcomas: A multi-modal integration analysis of comprehensive genomic profiling, targeted RNA-sequencing, and PD-L1 expression

(Press release, NeoGenomics Laboratories, MAY 26, 2026, View Source [SID1234666076])

On May 25, 2026 The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, reported that new data related to elacestrant and tagraxofusp will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New data exploring the safety and preliminary efficacy of elacestrant in combination with capivasertib in patients with ER+/HER2- PI3K/AKT/PTEN- pathway altered metastatic breast cancer (mBC) from the phase 1/2 ELEVATE study will be presented. Additional details on ongoing studies of elacestrant in combination, in the advanced setting, will be shared: ADELA (pivotal phase 3 combination with everolimus); ELECTRA (phase 1b/2 combination with abemaciclib in patients with brain metastases); and CAPELA (phase 2 combination with capecitabine). Lastly, an update from the ELEGANT study, exploring elacestrant as adjuvant treatment in node-positive early breast cancer with high risk of recurrence, will be presented at the congress.

Also accepted for presentation is new phase 2 tagraxofusp combination data in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), which will be presented by Naveen Pemmaraju, MD, Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. Additionally, Stemline’s partner, Karyopharm Therapeutics, will present a late-breaking oral presentation from the phase 3 SENTRY trial of selinexor in JAKi naïve patients with myelofibrosis (MF). Selinexor is marketed in the U.S. by Karyopharm Therapeutics, and in the EU by Stemline.

"The extensive oncology data that will be presented, encompassing both solid tumors and hematologic malignancies, highlights our dedication to tackling the most difficult-to-treat cancers with high unmet needs," said Elcin Barker Ergun, CEO of the Menarini Group. "Our focus remains on accelerating innovation to provide transformational, targeted therapies that offer meaningful advances to patients and the healthcare communities dedicated to their care."

See below for full details of upcoming presentations:

2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting

Lead Author

Abstract Title and ID

Presentation

Details

Elacestrant

Wassim McHayleh

Elacestrant in combination with capivasertib in patients with
ER+/HER2- advanced breast cancer: Update from ELEVATE, a
phase 1b/2 open-label, umbrella study

Abstract: 1098

June 1, 2026; 1:30 – 4:30 PM CT

Poster Board 212

Aditya Bardia

ELEGANT: Elacestrant versus standard endocrine therapy in
women and men with node-positive, estrogen receptor-positive
(ER+), HER2-negative (HER2-), early breast cancer with high risk of
recurrence in a global, multicenter, randomized, open-label phase 3 study

Abstract: TPS1153

June 1, 2026; 1:30 – 4:30 PM CT

Poster Board 262a

Antonio Llombart-
Cussac

ADELA: A double-blind, placebo-controlled, randomized phase 3

trial of elacestrant + everolimus versus elacestrant + placebo in

ER+/HER2- advanced breast cancer patients with ESR1-mutated
tumors progressing on endocrine therapy + CDK4/6i*#

Abstract: TPS1154

June 1, 2026; 1:30 – 4:30 PM CT

Poster Board 262b

Nuhad Ibrahim

ELECTRA: An open-label multicenter, phase 1b/2 study of

elacestrant in combination with abemaciclib in patients with brain

metastasis from ER+/HER2- breast cancer

Abstract: TPS1155

June 1, 2026; 1:30 – 4:30 PM CT

Poster Board 263a

Kristina Fanucci

CAPELA: A phase II multicenter open-label randomized study of

capecitabine in combination with elacestrant versus capecitabine

alone in advanced estrogen receptor (ER)–positive breast cancer

(TBCRC 070)*

Abstract: TPS1156

June 1, 2026; 1:30 – 4:30 PM CT

Poster Board 263b

Tagraxofusp

Naveen Pemmaraju

A Phase II Trial of Tagraxofusp, Hyper-CVAD, and Venetoclax for

Patients with Newly Diagnosed or Relapsed/Refractory BPDCN*

Abstract: 6502

Oral Presentation

June 2, 2026; 10:09 – 10:21 am CT

Selinexor

John Mascarenhas

Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis:

Phase 3 SENTRY trial*

Abstract: LBA6500

Oral Presentation

June 2, 2026; 9:45 am – 12:45 pm CT

*Denotes investigator sponsored research or collaborative research
#The ADELA study is a pivotal study co-sponsored with MEDSIR

About The Elacestrant Clinical Development Program
Elacestrant is also being investigated in several company-sponsored clinical trials in breast cancer disease, alone or in combination with other therapies. ELEGANT (NCT06492616) is a phase 3 trial evaluating the effectiveness of elacestrant versus standard endocrine therapy in women and men with node-positive, ER+, HER2- early breast cancer with high risk of recurrence. ADELA (NCT06382948) is a phase 3 randomized, double-blinded trial evaluating elacestrant in combination with everolimus in patients with ER+, HER2- mBC with ESR1-mut tumors. ELEVATE (NCT05563220) is a phase 1b/2 clinical trial evaluating the safety and efficacy of elacestrant combined with alpelisib, everolimus, capivasertib, palbociclib, ribociclib or abemaciclib. ELECTRA (NCT05386108) is an open-label phase 1b/2, multicenter study evaluating elacestrant in combination with abemaciclib in patients with ER+, HER2- breast cancer. The phase 2 portion evaluates this treatment regimen in patients with brain metastases. ELCIN (NCT05596409) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, HER2- advanced/metastatic breast cancer who received one or two prior hormonal therapies and no prior CDK4/6 inhibitors in the metastatic setting. Elacestrant is also being evaluated in additional investigator-led trials, in trials conducted in collaboration with other companies, in metastatic breast cancer as well as in early disease.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc.
at [email protected]. All of the relevant information can be found at View Source

Full prescribing information for elacestrant can be found at View Source

Full prescribing information for selinexor can be found at View Source

Full prescribing information for tagraxofusp can be found at View Source

(Press release, Menarini, MAY 25, 2026, View Source [SID1234666036])

On May 25, 2026 Pierre Fabre Laboratories reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the approval of BRAFTOVI (encorafenib) in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC). The positive opinion will be submitted to the European Commission (EC) with a decision on EU marketing authorisation expected later this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eric Ducournau, Chief Executive Officer, Pierre Fabre Laboratories, said: "Today’s positive CHMP opinion marks an important step towards a targeted approach for patients with BRAFV600E-mutant metastatic colorectal cancer. If approved, it would be the only approved targeted therapy in the EU for this patient population in the first-line setting. This milestone reflects Pierre Fabre Laboratories’ commitment to advancing meaningful innovation in oncology and to working in close partnership with the scientific and medical community to address areas of high unmet need."

The CHMP positive opinion is based on results from the Phase 3 BREAKWATER trial which assessed the efficacy and safety of BRAFTOVI in combination with cetuximab and mFOLFOX6 in patients with previously untreated BRAFV600E-mutant mCRC, compared with oxaliplatin-based chemotherapy, with or without bevacizumab.

The regimen of BRAFTOVI in combination with cetuximab and mFOLFOX6 showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy with or without bevacizumab (median PFS 12.8 vs. 7.1 months; hazard ratio [HR] 0.53; 95% confidence interval [CI], 0.41 to 0.68; P<0.001), and demonstrated a statistically significant improvement in the dual primary endpoint of ORR in the primary analysis set.

(Press release, Pierre Fabre, MAY 25, 2026, View Source [SID1234666038])

On May 24, 2026, Viridian Therapeutics, Inc. (the "Company") reported to have entered into a Commercial Manufacturing Services Agreement (the "Agreement") with WuXi Biologics (Hong Kong) Limited ("WuXi Biologics") pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for commercial use (the "Product"), if approved. Wuxi Biologics will be a non-exclusive supplier of the Product to the Company and the Company may procure the Product from one or more alternate manufacturers of the Product.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the Agreement, the Company will provide rolling forecasts of volume requirements to WuXi Biologics on a monthly basis (each, a "Forecast"). A portion of each Forecast will be considered a binding and non-cancellable commitment of the Company. The parties have agreed to volume-based pricing under the Agreement. The Product service fee will remain fixed until December 31, 2026 and thereafter may be annually adjusted based on a volume-based structure. The Company will also reimburse WuXi Biologics for certain pass-through costs.

The Agreement has an initial term of five years and will automatically renew for successive five-year periods unless either party provides notice of non-renewal at least 24 months prior to the expiration of the initial term or any renewal period. The Company may terminate the Agreement upon 30 days’ prior notice to WuXi Biologics if there is a change in applicable laws that materially and adversely impacts WuXi’s Biologics ability to perform services under the Agreement. Additionally, each party may terminate the Agreement upon an uncured material breach of the Agreement by the other party or upon the other party’s insolvency or bankruptcy.

The Agreement contains customary provisions relating to, among other things, delivery, quality, change procedures, regulatory compliance, confidentiality, dispute resolution, warranties, and indemnification.

The foregoing description of the terms of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the period ended June 30, 2026.

(Filing, Viridian Therapeutics, MAY 24, 2026, View Source [SID1234666059])

On May 22, 2026 Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, reported the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing includes leading U.S. biotechnology institutional investors and mutual funds.

Morgan Stanley acted as the lead book-running manager and BofA Securities acted as book-running manager for the offering. LifeSci Capital, Mizuho and Needham & Company acted as co-lead managers for the offering.

The securities in the registered offering were offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms of the registered offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Immix Biopharma, MAY 22, 2026, View Source [SID1234666011])